Skin Inflammation and PK of Azithromycin

• Status: Not yet recruiting
• Trial end date: 2026-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the tissue distribution of azithromycin in healthy, artificially inflamed and actually infected tissue of humans.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• • Men and women aged ≥18 and <55 years

• BMI ≥18 and ≤30 kg/m2

• Normal (or clinically irrelevant abnormal) findings in medical history and physical examination

• Women with child-bearing potential: use of effective contraception

• Laboratory parameters within the given reference range (or abnormal findings which are irrelevant for study purposes in the Investigator's opinion)

Exclusion Criteria:

• Known or suspected allergy to lipopolysaccharide, imiquimod, or sticking plasters

• Only Part 0c: Known or suspected allergy to local anesthetics

• History of severe allergic or anaphylactic reactions to any medication • Blood donation within the last 4 weeks before the study

• Treatment with an investigational drug within three weeks before the study

• Smoking of more than 5 cigarettes per day

• Regular use of medication or abuse of alcohol

• Use of any medication within one week before the study

• Symptoms of a clinically relevant illness in the 3 months before the study

• Liver or kidney dysfunction

• Pregnancy

• History of autoimmune diseases (especially psoriasis)

• Other objections to participating in the study in the opinion of the Investigator